Dr. Reddy’s Launches Generic Reclast Injection

Dr. Reddy’s Laboratories announced the launch of Zoledronic Acid Injection, the generic version of Novartis‘ Reclast.

Reclast is a bisphosphonate indicated to treat postmenopausal osteoporosis; to reduce the incidence of new clinical fractures in patients at high risk of fractures (those with recent low–trauma hip fracture); to prevent osteoporosis in postmenopausal women; to increase bone mass in men with osteoporosis; and to treat Paget’s disease of bone in men and women. Also, it is indicated to treat and prevent glucocorticoid-induced osteoporosis in men and women expected to be on glucocorticoids for >12 months.

Zoledronic Acid Injection is available in a 5mg/100mL strength in single-use vials for intravenous infusion.

For more information call (908) 203-4933 or visit www.drrreddys.com